Toronto Dominion Bank Raises Holdings in Moderna, Inc. (NASDAQ:MRNA)

Toronto Dominion Bank grew its holdings in shares of Moderna, Inc. (NASDAQ:MRNA - Free Report) by 23.7% in the 3rd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 131,477 shares of the company's stock after acquiring an additional 25,177 shares during the quarter. Toronto Dominion Bank's holdings in Moderna were worth $8,787,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds have also recently made changes to their positions in the stock. State Street Corp increased its position in Moderna by 12.1% during the 3rd quarter. State Street Corp now owns 16,847,212 shares of the company's stock worth $1,125,899,000 after purchasing an additional 1,823,276 shares in the last quarter. Geode Capital Management LLC increased its holdings in shares of Moderna by 2.6% during the third quarter. Geode Capital Management LLC now owns 7,069,580 shares of the company's stock worth $470,670,000 after buying an additional 178,115 shares in the last quarter. Wellington Management Group LLP lifted its stake in shares of Moderna by 21.0% in the 3rd quarter. Wellington Management Group LLP now owns 5,224,685 shares of the company's stock valued at $349,166,000 after acquiring an additional 906,114 shares during the last quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC boosted its holdings in shares of Moderna by 0.5% during the 3rd quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 3,890,812 shares of the company's stock valued at $260,023,000 after acquiring an additional 19,819 shares in the last quarter. Finally, The Manufacturers Life Insurance Company grew its position in Moderna by 6.2% during the 3rd quarter. The Manufacturers Life Insurance Company now owns 3,073,934 shares of the company's stock worth $205,431,000 after acquiring an additional 178,939 shares during the last quarter. Institutional investors own 75.33% of the company's stock.

Moderna Stock Down 2.3 %

Shares of NASDAQ MRNA traded down $0.99 during midday trading on Friday, hitting $41.83. 4,862,132 shares of the stock traded hands, compared to its average volume of 4,977,354. The company has a debt-to-equity ratio of 0.05, a quick ratio of 4.20 and a current ratio of 4.39. Moderna, Inc. has a one year low of $35.80 and a one year high of $170.47. The business has a 50 day moving average price of $48.62 and a two-hundred day moving average price of $85.02. The company has a market cap of $16.10 billion, a PE ratio of -7.19 and a beta of 1.58.

Moderna (NASDAQ:MRNA - Get Free Report) last released its quarterly earnings data on Thursday, November 7th. The company reported $0.03 earnings per share for the quarter, topping the consensus estimate of ($1.89) by $1.92. The firm had revenue of $1.90 billion for the quarter, compared to the consensus estimate of $1.25 billion. Moderna had a negative net margin of 43.77% and a negative return on equity of 17.68%. The business's revenue was up 3.8% on a year-over-year basis. During the same quarter in the prior year, the company posted ($1.39) earnings per share. On average, equities analysts predict that Moderna, Inc. will post -9.3 EPS for the current year.

Analysts Set New Price Targets

A number of brokerages have recently commented on MRNA. Barclays cut their price target on Moderna from $125.00 to $111.00 and set an "overweight" rating on the stock in a research note on Friday, November 8th. Leerink Partners reduced their target price on shares of Moderna from $60.00 to $48.00 and set an "underperform" rating on the stock in a report on Tuesday, September 17th. Bank of America reaffirmed an "underperform" rating and set a $41.00 price target on shares of Moderna in a research note on Tuesday. Jefferies Financial Group reduced their price objective on shares of Moderna from $65.00 to $55.00 and set a "hold" rating on the stock in a research note on Tuesday, October 15th. Finally, JPMorgan Chase & Co. cut their target price on Moderna from $59.00 to $45.00 and set an "underweight" rating on the stock in a report on Tuesday, November 26th. Four analysts have rated the stock with a sell rating, eleven have given a hold rating, five have issued a buy rating and one has issued a strong buy rating to the company's stock. According to data from MarketBeat.com, Moderna presently has a consensus rating of "Hold" and a consensus target price of $79.50.

Insider Buying and Selling at Moderna

In other news, CFO James M. Mock sold 715 shares of Moderna stock in a transaction on Monday, October 7th. The stock was sold at an average price of $60.12, for a total transaction of $42,985.80. Following the sale, the chief financial officer now directly owns 9,505 shares in the company, valued at $571,440.60. The trade was a 7.00 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, insider Shannon Thyme Klinger sold 1,418 shares of the business's stock in a transaction dated Friday, November 29th. The stock was sold at an average price of $42.79, for a total transaction of $60,676.22. Following the completion of the transaction, the insider now directly owns 19,717 shares in the company, valued at $843,690.43. This trade represents a 6.71 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last quarter, insiders sold 3,379 shares of company stock worth $158,195. Insiders own 15.70% of the company's stock.

Moderna Company Profile

Moderna, Inc, a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines.